Communiqué de presse
DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma
Initial dose escalation results from first-in-human phase 1 trial of DS-6000, Daiichi Sankyo’s fifth DXd ADC in clinical development, […]